Financial Performance - Total revenue for Q3 2025 was $161.7 million, with BRIUMVI U.S. net revenue at $152.9 million, representing 84% growth year-over-year[5] - The company raised its full-year 2025 global revenue target to approximately $600 million, up from a prior guidance of $585 million[6] - BRIUMVI U.S. net product revenue for the full year 2025 is now targeted at approximately $585 million, an increase from the previous guidance of $570 - $575 million[4] - Product revenue for Q3 2025 reached $159.3 million, a 91.2% increase from $83.3 million in Q3 2024[44] - Total revenue for the nine months ended September 30, 2025, was $423.7 million, compared to $220.8 million for the same period in 2024, reflecting a 92.0% growth[44] - Operating income for Q3 2025 was $29.4 million, up from $12.4 million in Q3 2024, representing a 136.5% increase[44] - Net income for Q3 2025 was $390.9 million, significantly higher than $3.9 million in Q3 2024, driven by a non-recurring income tax benefit of approximately $365.0 million[13] - Basic net income per share for Q3 2025 was $2.69, compared to $0.03 in Q3 2024, marking a significant improvement[44] Expenses - Research and development expenses for Q3 2025 were approximately $40.9 million, compared to $20.1 million in Q3 2024, reflecting increased costs in clinical trials and development[13] - Selling, general and administrative expenses for Q3 2025 were approximately $63.4 million, up from $42.0 million in Q3 2024, primarily due to increased marketing and personnel costs[13] - The company reported a total cost of revenue of $28.1 million for Q3 2025, compared to $9.3 million in Q3 2024, reflecting increased operational costs[44] - Research and development expenses for the nine months ended September 30, 2025, were $119.0 million, up from $70.4 million in the same period of 2024, indicating a focus on innovation[44] Shareholder Actions - The company completed a $100 million share repurchase program, purchasing approximately 3.5 million shares at an average price of $28.55 per share, and authorized an additional $100 million program[2] Market and Product Development - BRIUMVI is now approved in multiple international markets, including the European Union, United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates[5] - The company commenced patient enrollment into the Phase 3 pivotal program for subcutaneous ublituximab and completed enrollment for the ENHANCE trial[5] - The company presented three data presentations at the 2025 ECTRIMS annual meeting, showcasing positive outcomes from ongoing clinical trials[5] Assets and Equity - Cash, cash equivalents, and investment securities totaled $178.3 million as of September 30, 2025, down from $311.0 million at the end of 2024[44] - Total assets increased to $1.025 billion as of September 30, 2025, compared to $577.7 million at the end of 2024[44] - Total equity rose to $607.2 million as of September 30, 2025, up from $222.4 million at the end of 2024[44]

Financial Performance - Genie Energy reported a 23.6% increase in revenue for Q3 2025, reaching $138.3 million compared to $111.9 million in Q3 2024[7]. - Adjusted EBITDA for Q3 2025 decreased by 39.5% to $8.2 million from $13.6 million in Q3 2024[7][8]. - Gross profit fell by 20.8% to $30.0 million, with gross margin decreasing to 21.7% from 33.9%[7][8]. - Net income attributable to Genie common stockholders decreased by 33.9% to $6.7 million, with diluted EPS dropping to $0.26 from $0.38[7][8]. - Genie Renewables' revenue decreased by 2.7% to $6.0 million, impacted by a shift away from commercial project development[13]. - Total revenues for Q3 2025 reached $138.3 million, a 23.6% increase from $111.9 million in Q3 2024[26]. - Gross profit for Q3 2025 was $30.0 million, down 20.1% from $37.9 million in Q3 2024[26]. - Net income attributable to Genie Energy Ltd. common stockholders for Q3 2025 was $6.7 million, a decrease of 33.9% compared to $10.2 million in Q3 2024[26]. - Electricity revenues increased to $126.6 million in Q3 2025, up 25.7% from $100.7 million in Q3 2024[26]. - Net income for the nine months ended September 2025 was $19,899,000, a decrease of 28.5% compared to $27,754,000 in 2024[28]. - Net cash provided by operating activities of continuing operations was $28,123,000, down 42.8% from $49,174,000 in the previous year[28]. - Adjusted EBITDA for the third quarter of 2025 was $10,500,000, a decrease of 32.3% compared to $15,500,000 in the third quarter of 2024[45]. - Non-GAAP net income attributable to Genie Energy Ltd. common stockholders for the third quarter of 2025 was $7,100,000, down 34.6% from $10,900,000 in the same quarter of 2024[46]. - Diluted earnings per share for the third quarter of 2025 was $0.26, compared to $0.38 in the third quarter of 2024, reflecting a decline of 31.6%[46]. Assets and Liabilities - The company reported a total of $394.1 million in assets as of September 30, 2025, compared to $371.3 million at the end of 2024[23]. - Current liabilities increased to $124.9 million as of September 30, 2025, from $109.8 million at the end of 2024[23]. - Cash and cash equivalents rose to $109.3 million as of September 30, 2025, compared to $104.5 million at the end of 2024[23]. - Total cash, cash equivalents, and restricted cash at the end of the period was $207,137,000, an increase of 7.9% from $193,097,000 in 2024[28]. Shareholder Returns - The company repurchased approximately 124,000 shares for $2.0 million during Q3 2025 and declared a quarterly dividend of $0.075 per share[6][9]. - The company declared dividends of $0.075 per common share for both Q3 2025 and Q3 2024[26]. Future Outlook - Genie Energy expects to achieve its annual guidance range of $40 million to $50 million in Adjusted EBITDA for the full year 2025, albeit at the low end of the range[7]. - The company is nearing the launch of its Lansing community solar project, expected to generate revenue in Q4 2025[4]. - The company anticipates continued growth in renewable energy solutions and market expansion in the upcoming quarters[20]. Operating Expenses and Investments - Operating expenses for Q3 2025 were $22.6 million, a decrease from $25.2 million in Q3 2024[26]. - Capital expenditures for the nine months ended September 2025 were $5,763,000, an increase of 43.3% compared to $4,025,000 in 2024[28]. - The company reported a net cash used in investing activities of $10,383,000, a decrease of 10.1% from $11,545,000 in the previous year[28]. - Stock-based compensation for the nine months ended September 2025 was $1,938,000, an increase of 12.5% from $1,723,000 in 2024[28]. - The company experienced a net loss from discontinued operations of $62,000, compared to a loss of $435,000 in the previous year[28].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 ABVC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 001-40700 | 26-001465 ...

IPO and Corporate Structure - The company completed its Initial Public Offering on April 2, 2025, issuing 2,250,000 Ordinary Shares at a price of US$4.50 per share, resulting in gross proceeds of US$10,125,000[185]. - The company underwent a reorganization effective February 23, 2023, consolidating its businesses in the UK and Hong Kong into an offshore corporate holding structure in anticipation of its IPO[168]. - The company transferred all issued and outstanding shares of its subsidiary, Grand Alliance International Limited, to Mr. Michael Lau for HKD$1.00, resulting in a reduction of GBP303,013 (US$415,768) in net liabilities[185]. Financial Performance - For the fiscal year ended June 30, 2023, total revenue was GBP 6,005,563, with retrofit revenue accounting for 91.48% of total revenue[239]. - For the fiscal year ended June 30, 2024, total revenue is projected to be GBP 9,601,471, with retrofit revenue expected to be GBP 8,460,981[239]. - For the fiscal year ended June 30, 2025, one customer accounted for 19.8% of total revenue, indicating a significant customer concentration risk[303]. - As of June 30, 2025, four customers accounted for 23.3%, 16.2%, 14.6%, and 13.0% of the total balance of contracts receivable, highlighting ongoing customer concentration[304]. - For the fiscal year ended June 30, 2025, two vendors accounted for 17.3% and 12.2% of total purchases, while in 2024, one vendor accounted for 17.1%[307]. - As of June 30, 2025, four vendors represented 20.6%, 16.0%, 13.0%, and 12.9% of the total balance of accounts payable[308]. Product and Service Offerings - The company has expanded its product offerings into carbon reduction solutions, including boiler optimization and energy monitoring[165]. - NVL's primary products include high-performance, energy-efficient LED lighting systems, which are targeted for commercial, industrial, and exterior applications[209][212]. - The company aims to innovate its product portfolio, including the development of a "smart ceiling" that integrates IoT-enabled devices for better resource management[223]. - The company’s LED products are designed to provide more light with less energy, contributing to reduced operational costs for clients[256]. - The company’s energy management systems significantly reduce indirect CO2 emissions, aiding clients in achieving sustainability goals[256]. - The company plans to launch multiple new products over the next two years, including EnergysWatch, EnergysMeter, and EnergysClimate, with various phases scheduled from Q1 2026 to Q1 2028[277]. Market and Competitive Landscape - The company has faced challenges due to Brexit, including potential loss of foreign investment and increased product costs when expanding into the European market[167]. - The market for energy-efficient lighting products is fragmented, with competition from manufacturers like Osram and Honeywell International[316]. - The company believes that the market from existing infrastructure for LED retrofitting is significantly larger than that from newly constructed buildings, targeting large national accounts for revenue generation[323]. Sales and Distribution Strategy - The company plans to expand its sales and distribution networks into the United States and Europe, leveraging its expertise in managing projects across multiple facilities[222][225]. - The company intends to utilize its expanded sales team in the UK to market and sell products and services to European customers[332]. - The company is expanding its energy management services, including electricity bill management and remote monitoring, to create additional revenue sources[301]. Regulatory and Compliance - The company is subject to UK GDPR regulations, which may impose penalties of up to £17.5 million or 4% of worldwide revenue for non-compliance[347]. - The company established a Data Protection Policy and a Data Breach Response Plan on November 1, 2022, to ensure compliance with data protection laws[356]. - The company must implement new safeguards for data transfers outside the EEA or UK, requiring significant effort and cost[350]. - The company is subject to additional privacy and consumer protection laws in the UK, which may affect its marketing strategies[352]. Operational Efficiency and Management - The company emphasizes quality and reliability in its LED lighting systems, which has helped retain existing customers and attract new ones[226]. - NVL's business model includes comprehensive project management services, from consultancy to installation and maintenance, differentiating it from competitors[220]. - The management team has extensive experience, with the CEO having over 15 years in the energy conservation solutions industry[230]. - The company maintains property insurance policies and considers its insurance coverage sufficient for its operations[343]. Research and Development - The company’s research and development teams are located in Hong Kong, focusing on technology development and market feasibility studies[274][275]. - The company does not currently maintain cybersecurity insurance, which may not be available on acceptable terms if sought in the future[359]. - The company relies heavily on third-party service providers for data security, which limits its ability to monitor their practices[354]. Customer Engagement and Warranty - The company provides a product warranty for a period of 5 years and a workmanship warranty for 1 year from project completion[262]. - There were no material warranty claims made during the fiscal years ended June 30, 2023, 2024, and 2025[273]. - NVL has not experienced any warranty claims on OEM suppliers in the last three years, indicating strong product reliability[310].

Financial Performance - Net income attributable to Loews Corporation for Q3 2025 was $504 million, or $2.43 per share, compared to $401 million, or $1.82 per share in Q3 2024, representing a 25.7% increase in net income [142]. - For the nine months ended September 30, 2025, net income attributable to Loews Corporation was $1,265 million, or $6.03 per share, compared to $1,227 million, or $5.54 per share in the same period of 2024, reflecting a 3.1% increase [142]. - Net income attributable to Loews Corporation for Q3 2025 was $371 million, compared to $259 million in Q3 2024, representing a 43.2% increase [156]. - Core income for Q3 2025 was $409 million, up from $293 million in Q3 2024, reflecting a 39.6% year-over-year growth [156]. - For the nine months ended September 30, 2025, net income attributable to Loews Corporation was $897 million, compared to $860 million for the same period in 2024, a 4.3% increase [157]. - Core income for the nine months ended September 30, 2025, was $1.025 billion, up from $974 million in 2024, marking a 5.2% increase [157]. Insurance Operations - CNA Financial's insurance premiums for Q3 2025 were $2,783 million, up from $2,593 million in Q3 2024, marking a 7.3% increase [146]. - The total revenues for CNA Financial in Q3 2025 were $3,817 million, compared to $3,618 million in Q3 2024, reflecting a 5.5% increase [146]. - The underwriting gain for Q3 2025 was $194 million, compared to a gain of $68 million in Q3 2024, indicating a significant improvement [159]. - The combined ratio for Q3 2025 was 92.8%, improving from 97.2% in Q3 2024, demonstrating enhanced underwriting performance [159]. - The loss ratio for Q3 2025 was 63.4%, compared to 66.7% in Q3 2024, indicating improved loss management [159]. - Gross written premiums for Q3 2025 totaled $3.591 billion, slightly down from $3.595 billion in Q3 2024 [159]. - New business written in Q3 2025 amounted to $549 million, compared to $547 million in Q3 2024, showing stable growth [159]. Investment Income - Net investment income for CNA Financial in Q3 2025 was $638 million, compared to $626 million in Q3 2024, indicating a 1.9% increase [146]. - For the nine months ended September 30, 2025, CNA's net investment income was $1,904 million, compared to $1,853 million in the same period of 2024, a 2.8% increase [146]. - Net investment income for the nine months ended September 30, 2025, was $1,172 million, an increase from $1,090 million in the comparable 2024 period [176]. - CNA's total fixed income securities net investment income was $1.624 billion for the nine months ended September 30, 2025, compared to $1.555 billion in 2024 [244]. - CNA's net investment income increased by $12 million and $51 million for the three and nine months ended September 30, 2025, compared to the same periods in 2024 [244]. Capital Expenditures and Projects - Boardwalk Pipelines has growth projects expected to increase capacity by 4.2 billion cubic feet per day at a cost of approximately $3.0 billion, scheduled for completion through 2029 [192]. - The Kosciusko Junction Project is expected to increase capacity by 1.2 Bcf/d and has an expected in-service date in the first half of 2029 [194]. - The Texas Gateway Project is expected to increase capacity by approximately 1.5 Bcf/d with an expected in-service date in the second half of 2029 [202]. - The Eunice – Iowa project is expected to increase capacity by approximately 0.1 Bcf/d with an expected in-service date in the first half of 2027 [198]. - The Ohio Power Plant Project is expected to increase delivery capacity by approximately 0.3 Bcf/d with an expected in-service date in the first half of 2028 [200]. - Boardwalk Pipelines' capital expenditures were $222 million for the nine months ended September 30, 2025, compared to $292 million in 2024 [234]. Cash Flow and Dividends - CNA's cash provided by operating activities was $1.9 billion for the nine months ended September 30, 2025, unchanged from 2024, driven by increased premiums collected and higher cash from investment earnings [227]. - CNA paid cash dividends of $3.38 per share during the nine months ended September 30, 2025, including a special cash dividend of $2.00 per share [228]. - Continental Casualty Company paid dividends of $755 million and $635 million during the nine months ended September 30, 2025 and 2024, respectively [229]. - Interest expenses for the nine months ended September 30, 2025, decreased by $18 million to $54 million, attributed to the pre-financing of a debt maturity [213]. - The Parent Company's cash and investments totaled $3.6 billion as of September 30, 2025, an increase from $3.3 billion at the end of 2024 [224]. Operational Challenges and Adjustments - The corporate segment reported a net income of $42 million for Q3 2025, down from $73 million in Q3 2024, primarily due to lower investment income [142]. - For the nine months ended September 30, 2025, core results decreased by $66 million, primarily due to a $106 million after-tax charge related to unfavorable net prior year loss reserve development [185]. - Long-term care reserves increased by $7 million and $15 million for the three months ended September 30, 2025 and 2024, respectively, due to cash flow assumption updates [184]. - The enactment of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, has not materially impacted the company's results of operations or financial condition [258]. - Forward-looking statements in the report are subject to various risks and uncertainties that could cause actual results to differ materially from projections [259]. - The company emphasizes that certain accounting estimates may be adjusted in the future based on new information and changing circumstances [255].

Financial Performance - For the three months ended September 30, 2025, product revenue increased by $2.5 million (9%) to $32.0 million compared to the same period in 2024[126]. - For the nine months ended September 30, 2025, product revenue decreased by $0.8 million (1%) to $82.8 million compared to the same period in 2024[127]. - The company reported a net loss of $93.8 million for the nine months ended September 30, 2025, compared to a net loss of $45.6 million for the same period in 2024[126]. - License and other revenue for the three months ended September 30, 2025 increased by $2.7 million (30%) compared to the same period in 2024, primarily due to increased milestone-related revenue[130]. - License and other revenue for the nine months ended September 30, 2025 decreased by $1.9 million (6%) compared to the same period in 2024, primarily due to decreased milestone-related revenue[131]. - Total operating expenses for the three months ended September 30, 2025 decreased by $5.8 million (9%) compared to the same period in 2024[132]. - Research and development expenses for the three months ended September 30, 2025 decreased by $5.6 million (15%) compared to the same period in 2024, driven by a reduction in clinical trial costs for selinexor in multiple myeloma[136]. - Selling, general and administrative expenses for the three months ended September 30, 2025 decreased by $1.0 million (4%) compared to the same period in 2024[141]. - Interest expense for the nine months ended September 30, 2025 increased by $7.0 million (27%) compared to the same period in 2024[143]. - Research and development expenses for the nine months ended September 30, 2025 decreased by $12.0 million (11%) compared to the same period in 2024, mainly due to reduced clinical trial costs[137]. Cash and Financing - As of September 30, 2025, the company had an accumulated deficit of $1.7 billion[120]. - The company had $112.5 million outstanding under its senior secured term loan with a maturity date in May 2028 following the financing transactions[122]. - Financing transactions in October 2025 included $27.5 million in new term loan borrowings and convertible debt, and a private placement for approximately $8.8 million[121]. - The company raised approximately $8.8 million through a private placement of 1,487,917 shares of common stock at $5.88 per share on October 7, 2025[152]. - The company issued $15.0 million in new 9.00% senior secured convertible notes due 2028, with interest payable quarterly starting December 31, 2025[153]. - Future obligations include $152.4 million related to the Amended Credit Agreement through May 2028 and $136.1 million related to the 2029 Notes through May 13, 2029[166]. - As of September 30, 2025, the company had $45.9 million in cash, cash equivalents, and investments, reflecting a $7.4 million benefit from interest and royalties paid in kind[146]. - The company expects to fund its current operating plans into the second quarter of 2026 with existing cash and cash flows from product revenue[164]. - There is substantial doubt regarding the company's ability to continue as a going concern within one year after the issuance of the financial statements due to uncertainty in funding availability[163]. Operational Updates - The company completed enrollment in the Phase 3 SENTRY trial in September 2025, with top-line data expected in March 2026[117]. - The company plans to continue developing selinexor for multiple high unmet need cancer indications, including myelofibrosis and endometrial cancer[119]. - The company is focusing resources on prioritized late-stage programs, putting further development of the eltanexor program on hold[119]. - The company expects net product revenue in Q4 2025 to be consistent with Q3 2025 due to stable gross-to-net adjustments and demand[129]. - The company expects license and other revenue to decrease in the fourth quarter of 2025 compared to the third quarter of 2025[131]. - The company anticipates that total other (expense) income, net will remain relatively consistent in the fourth quarter of 2025 compared to the third quarter of 2025, excluding the impact of Financing Transactions[145]. Market Risks - The primary market risk exposure is interest rate sensitivity, with an immediate 100 basis point shift in interest rates expected to have no material effect on the fair market value of the investment portfolio[167]. - The company does not believe its cash, cash equivalents, and investments have significant risk of default or illiquidity, but acknowledges potential future adverse changes[168]. - The company is exposed to market risk related to fluctuations in foreign currency exchange rates due to contracts with organizations in Canada, the UK, and Europe[169]. - The company does not currently hedge its foreign currency exchange rate risk, which may impact financial performance[169]. Cash Flow - Net cash used in operating activities decreased by $38.1 million to $(63,541) thousand for the nine months ended September 30, 2025, a 38% improvement year-over-year[148]. - Net cash provided by investing activities decreased by $42.3 million to $38,378 thousand for the nine months ended September 30, 2025, a 52% decline compared to the previous year[149]. - The company received $8.2 million in milestone payments under license and distribution agreements during the nine months ended September 30, 2025[157]. - Total other (expense) income, net for the three months ended September 30, 2025 increased by $12.1 million compared to the same period in 2024, primarily due to the remeasurement of embedded derivatives and liability-classified common stock warrants[144].

Exhibit 99.1 Cipher Mining Provides Third Quarter 2025 Business Update Third Quarter 2025 Revenue of $72m and Non-GAAP Adjusted Earnings of $41m Executed 15-Year data center campus lease with Amazon Web Services to support AI workloads Secured Majority Ownership in Joint Venture to Develop 1-Gigawatt Site in West Texas NEW YORK— November 3, 2025 —Cipher Mining Inc. (NASDAQ: CIFR) ("Cipher" or the "Company") today announced its third quarter 2025 financial results, as well as an update on its operations and ...

Investor and Media Relations: Patricia Figueroa Exhibit 99.1 +1 (617) 747-3300 ir@amg.com pr@amg.com AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended 2025 Company reports Diluted EPS of $6.87, Economic EPS of $6.10 in the third quarter of 2025 WEST PALM BEACH, FL, November 3, 2025 — AMG, a strategic partner to leading independent investment management firms globally, today reported its financial and operating results for the third quarter and nine months ended Septembe ...

Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY ® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI ® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer's disease agitation submitted to the FDA Co ...

Exhibit 99.1 November 3, 2025 Fellow Shareholders: We are thrilled with our third quarter financial performance and execution throughout the organization. In North America, we delivered total revenue of $368.6 million and 1.63 million paid subscribers, our highest-ever third quarter subscriber count. In Rest of World we delivered total revenue of $8.6 million and 342,000 paid subscribers. In addition to this strong top-line performance we delivered Net loss of $18.9 million and Adjusted EBITDA (AEBITDA) of ...